Clinical Trial Update: Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update investigating addition of ISIS 14803 to peginterferon and ribavirin in chronic hepatitis C patients who did not adequately respond to the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ISIS 14803 (ISIS 14803)
• Peginterferon (Pegylated interferon)
• Ribavirin (ribavirin)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hepatitis C, Chronic | Phase 1, Phase 2 | Status: COMPLETED